Key result
Abnormal potassium linked to ~2.3-fold higher odds of refractory ascites in cirrhotic patients.
Why the study?
Multiple therapies exist for refractory ascites due to cirrhotic portal hypertension, making it challenging for providers to select the appropriate treatment for each specific patient.
Cohort (n=179)
No
Refractory ascites is a costly and debilitating condition that occurs most frequently in the setting of substantial cirrhotic portal hypertension, where it portends a poor prognosis. Many treatment options are available, among them medical management, serial large volume paracenteses, transjugular intrahepatic portosystemic shunts, and implanted drainage devices. Although the availability of multiple therapies ensures that most patients will achieve satisfactory results, it can be challenging for the provider to select the appropriate treatment for each specific patient. This article reviews the available therapeutic options for refractory ascites and incorporates available data and clinical experience to suggest a linear stepwise management approach to enhance patient outcomes.
No takes yet. Share an insight, caveat, or question.
Madoff et al. (2021) conducted a cohort in Cirrhotic ascites (with refractory ascites or spontaneous bacterial peritonitis) (n=179). Abnormal serum potassium level (< 3.5 or > 5.5 mEq/L) vs. Normal serum potassium level (3.5-5.5 mEq/L) was evaluated on Development of refractory ascites (OR 2.27, 95% CI 1.06-4.84, p=0.034). Abnormal serum potassium independently predicted refractory ascites (OR 2.27, 95% CI 1.06-4.84, P=0.034), while GI bleeding (OR 2.59) and platelets <50,000/µL (OR 3.27) predicted SBP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: